Posture-Triggered Abdominal Compression for nOH — viability

The chair: the investor, and the operator who has to run this as a business.

How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-019.md: the number is the claim's position in its ## Claims list, and the tag is copied from that claim as it stands at build time, never adjusted here. A [no claim] marker means nothing in the file speaks to the condition. No number appears here that isn't in a claim, and there is no ask slide. Where another lens holds a condition, this deck points at that deck rather than restating it. See docs/deck-spec.md.

What the file looks like from this chair. Since the last build the Verifier read the CMS (Centers for Medicare & Medicaid Services) DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) fee schedule and utilisation files, and one premise of the money model fell.

• Refuted: the pneumatic-compressor codes E0650 (a HCPCS code for durable medical equipment)-E0652 are not capped-rental items. The July 2026 fee schedule puts all three in the inexpensive-or-routinely-purchased category (IN) on every pricing line, so a placement in this family is paid as a one-time purchase, not a 13-month rental stream claim 117refuted.
• Now verified: a Medicare allowable is published for each of E0650, E0651, E0652 and the trunk appliance E0656 claim 107verified, and Medicare fee-for-service utilisation of E0650-E0652 is published claim 25verified.
• Unchanged: every verified coverage fact is an obstacle. No policy says yes to orthostatic hypotension.

The candidate was designed to close on the existing DME (durable medical equipment) benefit rather than on a coverage-at-authorization pathway. That makes Slides 2 and 3 the business, not a detail of it.

Slide 1 — Who pays, from which budget

Would have to be true: Medicare Part B (Medicare Part B), under the durable-medical-equipment benefit, would have to be the payer for most units; the device would have to qualify for that benefit category; Medicare Advantage (Medicare Advantage) would have to follow the same determination; and the beneficiary would carry the coinsurance, or the whole price where nothing pays.

Where it stands:

• Payer mix. That most prescribed patients are Medicare beneficiaries is an assumption claim 44unconfirmed. The age proxies on record are partial, none of them a payer-mix figure: median age 69 with 12 of 15 aged 65 or older in the Innsbruck binder trial claim 58verified, mean age 77 for Parkinson disease with nOH (neurogenic orthostatic hypotension) in claims data claim 83verified. MSA (multiple system atrophy) is counted from age 30 claim 80verified, so an under-65 share is plausible.
• Medicare Advantage. Whatever the Part B benefit-category and NCD (national coverage determination) outcome is, it binds Medicare Advantage basic benefits too claim 120verified.
• Benefit category. That the device is DME and separately billable is an assumption claim 32unconfirmed. That it meets the purpose and home-use conditions (3)-(5) of the 42 CFR 414.202 DME definition is unconfirmed: the definition text verifies, its application to this device does not claim 121unconfirmed. The controller's repeated-use and three-year-life conditions are a design commitment with no source yet claim 119unconfirmed.
• The beneficiary's share. That Medicare pays 80 percent of the lesser of charge and fee schedule, leaving the beneficiary 20 percent, is on record from the business case and not yet checked claim 138unverified. Whether patients pay that share, or the full price where nothing pays, is held in the desirability deck, Slide 4.

What would settle it: Claims 138 and 121 are eCFR-reachable text; a Verifier run on 42 CFR 414.210(a) settles 138. Benefit category itself is a DME MAC (durable medical equipment Medicare administrative contractor) benefit-category inquiry or a CMS coding decision, human-run. For payer mix, a CCW or registry age pull, human-attached; the market connector returns unverifiable by design.

If it's false: If the device is not DME, there is no Part B channel; the base case the candidate was designed around disappears and the only payer left is the patient (the cash routes in the business case). Factor 2 sits at 1/5 on verified evidence and would have no route to move.

Slide 2 — The three reimbursement questions

Would have to be true: Three separate things would each have to land: a HCPCS (Healthcare Common Procedure Coding System) code under which this device can be billed; an allowable under that code that pays for the controller and the garments it consumes; and a national or DME MAC coverage policy that reaches symptomatic nOH, an indication current policy does not cover.

Where it stands:

• Code exists: The family is real. E0650-E0652 and the trunk and chest appliances E0656 and E0657 were verified against the October 2026 Level II file, but the claim stays unconfirmed on its negative half, that no code specifically fits this device claim 10unconfirmed. Every non-segmental appliance descriptor names a limb and none names an abdominal or posture-triggered device, so billing needs CMS to accept a descriptor mismatch or issue a new code claim 115unconfirmed. That CMS will assign or accept a code is a future act claim 40unconfirmed.
• Payment amount: A published allowable now exists for each family code claim 107verified. The Verifier's note on the price claim records the non-rural new-purchase (NU) allowables across the contiguous states and DC as E0650 $872.43-$1,026.39, E0651 $1,112.52-$1,308.85 and E0652 $6,422.01-$7,555.31, allowed amounts and not payment; the claim itself stays unconfirmed because it is the Generator's assumption that this device prices in that range claim 23unconfirmed. The family is paid as a purchase, not a capped rental claim 117refuted. Which of the three codes this device takes is the open question, and the spread between them is wide: this deck puts on record that, as a single non-segmental bladder, it would take E0650, the lowest claim 140unverified.
• Coverage policy: NCD 280.6 (a Medicare national coverage determination number) covers lymphedema and chronic venous insufficiency with ulcers, after a documented four-week or six-month conservative-therapy trial claim 9verified. By its own device description it reaches an intermittently cycled arm or leg garment, not a sustained-pressure abdominal device claim 116verified. That some policy will reach nOH is a future act claim 41unconfirmed. The DME MAC LCD (local coverage determination) L33829 (a Medicare local coverage determination number) has never been read claim 118unconfirmed.

What would settle it:

• Code selection: a PDAC (Pricing, Data Analysis and Coding contractor) coding-verification request or a DME MAC coding enquiry on the E0650 reading (claim 140unverified), human-run; a CMS HCPCS application if no existing code is accepted.
• Coverage: the text of LCD L33829, then a coverage-reconsideration or NCD request, human-run and multi-month.
• Payment: now on file. The fee schedule settled existence; it cannot settle which line applies.

If it's false: Any one failing is enough. No code, no claim can be submitted. No coverage, a code with no payable indication. An allowable below cost of goods (Slide 3) makes each placement a loss. This slide is where the file's verified Factor 2 score of 1/5 comes from, and the refutation of claim 117refuted changes none of the coverage half: a purchase allowable is still not coverage.

Slide 3 — What one placement pays, and to whom

Would have to be true: Paid once as a purchase, the manufacturer's revenue per Medicare placement would have to exceed the fully loaded cost of one patient's system — the controller plus the garments it consumes over its service life — at the business case's volume and at one tenth of it, whether the manufacturer sells into a third-party supplier's inventory or enrols as a supplier itself.

Where it stands:

• The cadence. The rental-stream reading is refuted; the compressor family is category IN claim 117refuted. Under 42 CFR 414.220(b) an IN item paid through its rental line cannot earn more in total than its purchase allowable — on record, not yet checked claim 137unverified. Medicare does not replace a DME item for the same beneficiary within its reasonable useful lifetime, five years unless CMS sets another, so a controller is paid at most once per beneficiary per five years in ordinary use — also on record, unchecked claim 139unverified.
• The only recurring line. Whether Part B pays separately for replacement garments is unconfirmed; the Verifier notes the fee schedule prices appliance codes as separate lines, but separate payability is a policy-article rule nobody has read claim 122unconfirmed. That a garment lasts under twelve months, so each placement uses more than one a year, is an assumption claim 129unconfirmed. If the garment were coded as a trunk appliance, that half would be paid as a capped rental: E0656 is category CR on a rental line only claim 107verified.
• The system and its cost. The device is a controller, a single-patient multi-use garment and a charger claim 92unconfirmed. That its cost of goods sits below the family purchase allowable, at volume and at a tenth of volume, is open, and no cost figure exists anywhere in the file claim 96unconfirmed.
• The two channels. Through a third-party supplier, the manufacturer's revenue is the supplier's one-time acquisition price, below the NU allowable the supplier collects — on record from the business case claim 136unverified. The earlier capped-rental version of that condition stays on file with its premise contradicted claim 124unconfirmed. That a manufacturer may enrol and bill as a supplier under 42 CFR 424.57 is unconfirmed; the section as returned does not contain the word "manufacturer" claim 125unconfirmed.

What would settle it: Verifier runs on 42 CFR 414.220(b) and 414.210(f) for claims 137 and 139, which are eCFR text and take minutes. Acquisition-price quotes from accredited suppliers already billing E0650-E0652 for claim 136unverified, human-run. The cost side needs a costed bill of materials, which follows the feasibility deck's build.

If it's false: A device that loses money per placement is not rescued by volume, and under a purchase model there is no rental tail to recover it: the controller pays once in five years and only the garment line, if separately paid, recurs. The TAM (total addressable market) on Slide 4 then measures losses.

Slide 4 — TAM, decomposed

Would have to be true: Four factors would each have to be large enough — population, rate, price and reachable share — and the file carries a figure for only two. The Medicare volume anchor is a check on the result, not a factor in it.

Where it stands:

• Population: Parkinson disease is 572 per 100,000 aged 45 or older, about 680,000 US individuals in 2010, with a projection, not a count, of about 930,000 in 2020 claim 81verified. The file's headline figure of about one million is unconfirmed claim 21unconfirmed. MSA is 12.4 per 100,000, about 41,133 persons, on a one-claim definition and 5.7 per 100,000 on two claims claim 80verified. PAF (pure autonomic failure) has no figure; that a US-applicable published estimate exists is unconfirmed, with no paper named claim 133unconfirmed.
• Rate / incidence: OH (orthostatic hypotension) prevalence in Parkinson disease is 33%, neurogenic 26%, symptomatic about 20%, with 24.9-28% the file's own US-scoped range claim 22verified. The fraction still symptomatic after non-pharmacologic measures, which is the intended use's population, has no figure; that a published study reports it is on record from this deck claim 141unverified.
• Price: published allowables exist (Slide 2) claim 107verified; which one applies is open claim 140unverified; that the device prices in the family range is an assumption claim 23unconfirmed.
• Reachable share: no figure. Two of its three filters are the desirability deck's conditions claim 24unconfirmed.
• Volume anchor: now published. Medicare fee-for-service purchase beneficiaries are E0650 97, E0651 34,399 and E0652 6,792, service year not stated in the file claim 25verified. These are lymphedema and venous-disease volumes, not nOH patients, and a fee-for-service floor, never a market size. They say something uncomfortable about Slide 2: the code this device most plausibly takes is the one Medicare buys least.

What would settle it: A literature pull for the claim 141unverified and claim 133unconfirmed figures, then a Verifier literature-detail run on the named papers. CCW Parkinson prevalence, a human fetch. For share, primary research; no source in this repo settles it.

If it's false: Factor 3 is blank, not low, and cannot trip the TAM floor until scored. If price is the E0650 allowable and share is small, the best-evidenced part of the chain, the population, multiplies to a number that no longer carries the development programme on Slide 5. The class-2 population claims do not score until the pending corroborated decision.

Slide 5 — Capital to first dollar

Would have to be true: A prototype, bench work, a home feasibility study, a sham-controlled pivotal study, a De Novo (De Novo classification request) request, a HCPCS coding application and a coverage request would all have to be completed before the first Medicare dollar, and the contribution margin on US sales would then have to repay that fixed cost before a 510(k) (premarket notification) follower clears against the De Novo this programme creates.

Where it stands:

• Starting point. No prototype or data exists claim 8unconfirmed.
• Sequencing. No Medicare revenue until De Novo, code and coverage are all in place, and they cannot substantially run in parallel — an assumption claim 42unconfirmed. An IDE investigation is expected, not confirmed claim 47unconfirmed.
• Accelerators. None is in force. RAPID is a notice with comment closing 2026-10-13 claim 15verified; TCET is paused claim 16verified and was capped at about five a year claim 17verified; MCIT was repealed before it operated claim 18verified. RAPID also excludes a device under a controlling NCD claim 13verified and admits 510(k) devices only on a recent De Novo predicate claim 19verified.
• The margin condition is unconfirmed, and the Verifier notes the allowable side is now readable but is one input of several claim 123unconfirmed. That the pivotal study is the largest fixed cost is unconfirmed claim 128unconfirmed. Under a one-time purchase the margin has to be earned per new patient, not per rental month (Slide 3).
• The cost figure. No claim carries a dollar cost or a calendar for any step [no claim]. This deck states none.

What would settle it: A costed development plan, which is Stage 7 work for a human. Public inputs: FDA (US Food and Drug Administration) De Novo decision summaries for comparable Class II (FDA device class II) devices, and CMS's published HCPCS application cycle. A Q-Sub settles the IDE question (claim 47unconfirmed).

If it's false: The programme funds a predicate for followers. The file scores Factor 7 at 1/5 on verified evidence, and nothing on this slide is verified in the programme's favour.

Slide 6 — What stops a fast-follower

Would have to be true: Something would have to stop the next entrant — an exclusive licence to enforceable, granted claims in the Vanderbilt family, or claims of the candidate's own that are novel over published art — because otherwise the first De Novo is simply a predicate for the second company's 510(k).

Where it stands:

• The Vanderbilt family. US2015313608 is real, on abdominal venous-pooling compression, and live on a naive term to 2033-11-04; grant status and claim scope are unknown claim 26verified. Whether any member has issued and is in force is open claim 88unconfirmed, as is exclusive licensability claim 43unconfirmed.
• The candidate's own novelty. Whether that publication discloses posture-triggered activation is unconfirmed claim 90unconfirmed. A posture-triggered motor binder has already been published claim 86verified. The mechanism has been in public registered trials for years claim 6verified claim 7verified.
• A follower's route is written into the margin condition on Slide 5 claim 123unconfirmed.

The two open IP (intellectual property) questions pull in opposite directions: if nothing issued, the path is clear for this candidate and everyone else; if something issued, the moat belongs to whoever holds the licence.

What would settle it: USPTO (United States Patent and Trademark Office) file history and INPADOC family status for US2015313608, free and hours. A licensing enquiry to the rights holder, Tier 3. A patentability search against claim 86verified's publication, counsel work.

If it's false: Factor 5 stays at 1/5 and the case rests on first-mover time, which no claim sizes.

Slide 7 — Who is already there

Would have to be true: No incumbent — a drug patients stay on, an industry device sponsor already in orthostatic hypotension, or a pneumatic-compression maker with recent clearances under the same regulation — would be one step from this market, and the claim-stripped version of this hardware would have to be sellable to the same patients without FDA reading an orthostatic-hypotension intended use into it.

Where it stands:

• Drugs. Approval status and labelling are unconfirmed for want of a drug connector claim 11unconfirmed. Persistence is verified: median 303 days on droxidopa, 172 on midodrine claim 64verified. FDA determined PROAMATINE was not withdrawn for safety or effectiveness claim 63verified.
• An industry device sponsor. Isotech's ISO (International Organization for Standardization)-101 has a registered OH study, status unknown, no results claim 60verified.
• The competitor search found nothing, which is not an absence claim 34unconfirmed.
• IPC incumbents. Fifteen JOW clearances in two years from 14 applicants are on record, unconfirmed claim 91unconfirmed; the field search against them was never run claim 27unconfirmed. The incumbents' purchase volumes are on Slide 4 claim 25verified.
• The claim-stripped floor. The Class I truncal-orthosis regulation names abdominal orthoses and carries no haemodynamic indication claim 54verified. Whether a posture-triggered garment could be sold to nOH patients without 21 CFR (Title 21 of the Code of Federal Regulations) 801.4 reading an intended use into it is unconfirmed, and the Verifier records that the regulation text runs against it: it names "the design" of the article and "the circumstances surrounding the distribution" claim 127unconfirmed.

What would settle it: A human-attached registration-and-listing and financing pull; ClinicalTrials.gov sponsor searches against the JOW applicants; the Verifier on claim 91unconfirmed; a regulatory-counsel reading or a Q-Sub on 21 CFR 801.4 for the claim-stripped route.

If it's false: An incumbent with a cleared compressor, supplier relationships and a sales force reaches the indication faster than a new company. The claim-stripped route stops being a fallback. Factor 8 is 2/5, and the file's own note says that may understate the contest.

Slide 8 — The cheapest way to find out

Would have to be true: A costed bill of materials for one patient's controller plus five years of garments would have to come in below the new-purchase allowable of the code this device would actually bill under — and if that code is E0650, below the lowest allowable in the family.

Where it stands: The allowable side is now on file claim 107verified, with the figures in the Verifier's note on claim 23unconfirmed. Which code applies is on record from this deck claim 140unverified. The five-year horizon is the replacement rule claim 139unverified. The cost side is empty claim 96unconfirmed.

What would settle it: Two cheap moves, in either order. A PDAC or DME MAC coding enquiry on the E0650 reading (claim 140unverified), human-run and cheap in money though not in calendar. A desk-costed bill of materials for the controller from catalogue components (the operations chair's claim 97unconfirmed names the pump, valve and sensor) plus a garment estimate, which an engineer can draft before any prototype exists. Neither needs coverage to have been argued first.

If it's false: If a controller-plus-garments cost does not clear the E0650 allowable, the Part B base case fails on arithmetic before coverage is argued, unless the device is accepted under a higher-paying code. Slide 2's coverage question becomes moot for the purchase model.

Slide 9 — Where this deck outruns the file

Every condition above with nothing verified behind it that supports it. The verified claims on this deck are almost all obstacles or context — the refutation of claim 117refuted, the NCD's limits, the incumbent volumes — and those are not backing.

• The device is DME, separately billable, with Medicare the majority payer (Slide 1) — claim 32unconfirmed claim 121unconfirmed claim 119unconfirmed claim 44unconfirmed. Settled by a DME MAC benefit-category inquiry and a registry age pull.
• The beneficiary's 20 percent share (Slide 1) — claim 138unverified. Settled by a Verifier run on 42 CFR 414.210(a).
• A billable code is assigned or accepted (Slide 2) — claim 40unconfirmed claim 115unconfirmed claim 10unconfirmed. Settled by a PDAC or CMS coding decision.
• The code would be E0650, the lowest-paying (Slides 2, 4 and 8) — claim 140unverified. Newly on record from this deck. Settled by a PDAC coding-verification request.
• A coverage policy reaches symptomatic nOH (Slide 2) — claim 41unconfirmed claim 118unconfirmed. Settled by the L33829 text, then a coverage request.
• The purchase-model cadence: rental cannot exceed purchase, one controller per five years (Slide 3) — claim 137unverified claim 139unverified. Settled by Verifier runs on 42 CFR 414.220(b) and 414.210(f).
• Garments are paid separately and recur (Slide 3) — claim 122unconfirmed claim 129unconfirmed. Settled by DME MAC policy-article text and garment wear testing.
• Cost of goods below the allowable, in either channel (Slides 3 and 8) — claim 96unconfirmed claim 136unverified claim 125unconfirmed claim 92unconfirmed. Settled by a costed bill of materials, supplier quotes, and a CMS enrolment reading.
• PAF prevalence, and the fraction still symptomatic after non-pharmacologic measures (Slide 4) — claim 133unconfirmed claim 141unverified. Settled by naming the papers, then literature-detail.
• Price and reachable share (Slide 4) — claim 23unconfirmed claim 24unconfirmed. Share needs primary research.
• The development programme's cost and calendar (Slide 5) — [no claim]. A Stage 7 costed plan, human-run.
• Margin repays the fixed cost before followers (Slide 5) — claim 123unconfirmed claim 128unconfirmed claim 42unconfirmed.
• An exclusive licence to granted claims, or novel claims of the candidate's own (Slide 6) — claim 43unconfirmed claim 88unconfirmed claim 90unconfirmed. File history and a licensing enquiry.
• No incumbent a step away, and the claim-stripped route stays clean (Slide 7) — claim 34unconfirmed claim 91unconfirmed claim 127unconfirmed. A company pull and counsel.

Slides 1, 2 and 4 carry verified claims that bear on their condition in part: Medicare Advantage follows Part B, a published allowable exists for each code, and the Parkinson and MSA population and OH rate are known. Nothing verified supports Slides 3, 5, 6, 7 or 8.

Slide 10 — The load-bearing condition

If only one thing from this chair could be checked: whether the one-time Medicare purchase allowable of the code this device would actually bill under — E0650, the lowest in the family, if a single non-segmental bladder takes the non-segmental descriptor — exceeds the fully loaded cost of one patient's controller plus the garments it consumes claim 96unconfirmed claim 140unverified.

The previous build named coverage (claim 41unconfirmed) here, and coverage is still necessary: a code with no covered indication pays nothing, and the two verified coverage facts (claims 9 and 116) both say current policy does not reach this device. It moved because the refutation of claim 117refuted changed what coverage would buy.

• Under capped rental, a placement was a monthly stream; under category IN it is a single payment, and the controller is paid at most once per beneficiary in five years (claim 139unverified).
• The family's allowables span a wide range, and the code the device most plausibly takes sits at the bottom of it, with the smallest Medicare purchase volume (claim 25verified).
• This question can be answered before coverage is argued, and cheaply: a coding enquiry and a desk-costed bill of materials. If it fails, coverage opens a door to a loss; if it holds, coverage becomes the next question.

Naming it is not a recommendation, a gate, or a kill.